Mr. Autterson spent 25 years in the financial services industry where he was president of one of the largest state charted financial institutions in the country.

Mr. Autterson graduated from Michigan State University with a B.A. in Finance in 1980. He attended the University of Denver Graduate Tax Program. He began his career at First Trust Corporation, a subsidiary of Fiserv. He left in 1982 and joined a small team to charter a new Colorado state-chartered trust company as a subsidiary of New York-based financial services company Integrated Resources, Inc. In 1986 he became president of Resources Trust Company. In 1989, Resources Trust Company along with other assets owned by Integrated Resources, Inc. was acquired by Broad Inc, which subsequently became SunAmerica, Inc. SunAmerica was acquired by AIG in 1998 for $18 billion.

In May, 2001 Resources Trust Company was acquired by Fiserv from AIG. Prior to completing the sale, Resources Trust Company was one of the largest state-chartered, FDIC-insured depository trust companies in the country. It provided depository and custodial services to more than 200,000 clients, brought to the company by more than 15,000 registered independent financial advisors. Resources Trust Company held more than $20 billion in custodial assets and over $1.0 billion in deposits with more than 700 employees.

Matthew Autterson is a member of the Board of Directors of Falci Adaptive Motorsports (FAM). As a leader in Colorado’s business community, FAM represents Mr. Autterson’s current philanthropic interests following many years of leadership roles with the Board of the Denver Zoo, and Denver Zoological Foundation, the Webb-Waring Foundation and as Chairman of the Board of Directors of Denver Hospice. Mr. Autterson is a former member of the Young Presidents’ Organization (YPO) and World Presidents’ Organization (WPO).

Mr. Autterson is currently a Board Member, President and Chief Executive Officer of CNS Biosciences, Inc., founded in 2013 by neurosurgeon Scott Falci, M.D. CNS is a clinical-stage drug development company focusing on neuropathic pain.